1. Topalian , S. L. , Hodi , F. S. , Brahmer , J. R. , Gettinger , S. N. , Smith , D. C. , McDermott , D. F. , Powderly , J. D. , Carvajal , R. D. , Sosman , J. A. , Atkins , M. B. , Leming , P. D. , Spigel , D. R. , Antonia , S. J. , Horn , L. , Drake , C. G. , Pardoll , D. M. , Chen , L. , Sharfman , W. H. , Anders , R. A. , Taube , J. M. , … Sznol , M. ( 2012 ). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine, 366(26), 2443–2454 . Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., Leming, P. D., Spigel, D. R., Antonia, S. J., Horn, L., Drake, C. G., Pardoll, D. M., Chen, L., Sharfman, W. H., Anders, R. A., Taube, J. M., … Sznol, M. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine, 366(26), 2443–2454.
2. H.I. Assi A.O. Kamphorst N.M. Moukalled S.S. Ramalingam Immune checkpoint inhibitors in advanced non-small cell lung cancer Cancer 124(2) (2018) 248–261. H.I. Assi A.O. Kamphorst N.M. Moukalled S.S. Ramalingam Immune checkpoint inhibitors in advanced non-small cell lung cancer Cancer 124(2) (2018) 248–261.
3. The blockade of immune checkpoints in cancer immunotherapy
4. Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
5. Harnessing the immune system to improve cancer therapy